|
Volume 21, Issue 1 (January 2019) 21, 3–5; 10.4103/aja.aja_37_17
PSA screening - for whom and when?
Peter Albers
Department of Urology, Düsseldorf University Hospital, Heinrich-Heine-University, Moorenstr. 5, D-40225, Düsseldorf, Germany
Correspondence: Dr. P Albers (urologie@uni‐duesseldorf.de)
Date of Submission 14-Jun-2017 Date of Acceptance 15-Jun-2017 Date of Web Publication 05-Sep-2017
| Abstract |
|
Reasons for and against screening of prostate cancer have been discussed widely over the last decade. In 2014, the European Randomized Trial for Screening of Prostate Cancer (ERSPC) has reported a relative reduction of the cancer-specific survival of 27% in participants who definitely followed the screening protocol. This relative advantage has proven to be stable from year 7 to year 13 after the beginning of screening. Still, the disadvantages of overdiagnosis and overtreatment are the downsides of a population-based screening approach. But given the overall advantage of screening, a risk-adapted prostate-specific antigen (PSA) screening using a baseline PSA value at ages 45-50 may significantly reduce the number needed to diagnose maintaining the benefits of screening. PROBASE is a randomized risk-adapted screening trial currently ongoing in Germany to answer this important question.
Full Text |
PDF |
|
| |
| Browse: 1586 |
|
